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Background/Aims: Chronic obstructive pulmonary disease (COPD) is a major 
cause of mortality in the world. There are no population-based studies on long-
term mortality in COPD patients in Korea.
Methods: Using the large, population-based, National Health Insurance Ser-
vice-National Sample Cohort (NHIS-NSC), we identified COPD patients using the 
International Classification of Disease-Tenth Revision (ICD-10) and prescription 
details in the NHIS-NSC during 2003 to 2013. We analyzed the survival curves of 
COPD patients by sex, age, and cause of death.
Results: A total of 14,127 individuals older than 40 years were diagnosed with 
COPD. There were a total of 3,695 deaths (26.2%) in COPD patients during the 
study period. The 5-year mortality of COPD patients was 25.4% (29.9% in males 
and 19.1% in females). The mortality rate increased rapidly with age. The most 
common cause of death in COPD was chronic lower respiratory disease.
Conclusions: This study described long-term mortality in COPD patients in Ko-
rea. Higher mortality was observed in males, and it was closely related to age.
Keywords: Pulmonary disease, chronic obstructive; Mortality; Cause of death
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INTRODUCTION
Chronic obstructive pulmonary disease (COPD), charac-
terized by persistent respiratory symptoms and airflow 
limitation, is mainly caused by smoking or other envi-
ronmental exposures and is a major cause of chronic 
morbidity and mortality in the world [1]. The burden of 
COPD is expected to increase in the coming decades due 
to an aging population and longer exposure to COPD 
risk factors such as smoking or air pollution [2]. COPD 
was the third leading cause of death worldwide in 2015, 
when 3.2 million people died from the disease [3].
Although many studies have described COPD mortality, 
there are no population-based studies on the long-term 
mortality of COPD in Korea. The purpose of this study 
was to analyze long-term mortality in COPD patients over 
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10 years using a large population-based cohort.
METHODS
Source of data
Since 2000, the National Health Insurance Service 
(NHIS) in Korea has provided health insurance to nearly 
all people living in Korea. Consequently, a large amount 
of health-related data has accumulated in the NHIS da-
tabase, leading to establishment of a research database. 
The target population consists of 46,605,433 individ-
uals in the NHIS database system, from which a total 
of 1,025,340 participants were randomly sampled for a 
research database called the NHIS-National Sample Co-
hort (NSC). The NHIS-NSC included 2.2% of the total 
Korean population in 2002, following them for 12 years 
until 2013. We used this NHIS-NSC database to analyze 
mortality trends in COPD patients. This study was ap-
proved by the Institutional Review Board of National 
Health Insurance Service Ilsan Hospital (approval num-
ber: 2017-05-007). Written informed consent was waived 
by the board because data were de-identified and the 
study was retrospective in nature. 
Study population
Because the NHIS database did not include spirometry 
data considered essential for the diagnosis of COPD, 
we identified COPD patients using the International 
Classification of Disease-Tenth Revision (ICD-10) and 
prescription details in the NHIS-NSC (Fig. 1). Similar 
to previous studies [4-6], COPD patients were identi-
fied by having all of the following criteria: older than 
40 years; ICD-10 codes for COPD (J43-J44, except J430); 
and COPD medication use at least twice per year. COPD 
medications included long-acting muscarinic antago-
nists (LAMAs), long-acting beta-2 agonists (LABAs), in-
haled corticosteroids (ICS), ICS plus LABA, short-active 
muscarinic antagonists (SAMAs), short-acting beta-2 
agonists (SABAs), methylxanthines, systemic corticoste-
roids, and systemic beta agonists. We excluded COPD 
patients who were diagnosed in 2002, focusing on pa-
tients newly diagnosed with COPD from 2003 to 2013.
Determinants of disease and demographic factors
Demographic factors of COPD patients were analyzed 
at the time of COPD diagnosis. According to household 
income, socioeconomic status was divided into five cat-
egories. Region of residence was categorized to urban 
and rural area. Charlson comorbidity index was calcu-
lated as previously described [7].
Mortality
Patients were enrolled at the time of COPD diagnosis 
and followed until the end of the study period or death. 
The time of death was recorded by year and month. 
The immediate cause of death in the death certificate 
was used to classify the cause of death, which was divid-
ed into pneumonia (J12-J18), chronic lower airway dis-
ease (J40-J47), lung cancer (C34), cardiovascular disease 
(I20-I25, I30-52), cerebrovascular disease (I60-69), diabe-
tes mellitus (E10-14), and hypertension (I10-15) accord-
ing to the Korean Standard Classification of Disease and 
Cause of Death-Sixth revision. 
Statistical analysis
Descriptive statistics were performed for all variables. 
Annual COPD visits by sex and age were calculated. First 
visits with COPD were deemed newly diagnosed COPD 
and used for the incidence analysis. A Kaplan-Meier anal-
ysis was used to calculate overall survival of COPD by sex 
and age. The causes of death in COPD patients were also 
analyzed. All statistical analyses were performed with SAS 
software version 9.4 (SAS Institute, Cary, NC, USA).
1,025,304 Individuals in  NHIS-NSC in 2002
Followed-up during 2002–2013
Inclusion criteria
1. ICD-10 code for COPD
2. COPD medication more than twice per year
Identified new 14,127 COPD patients during 2003–2013
 Washed out COPD patients in 2002
Figure 1. Flow chart of inclusion criteria for chronic obstruc-
tive pulmonary disease (COPD) identification. NHIS-NSC, Na-
tional Health Insurance Service-National Sample Cohort; ICD-
10, International Classification of Disease-Tenth Revision.
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RESULTS
Baseline demographics
Table 1 shows the baseline demographics of COPD pa-
tients. A total of 14,127 individuals were diagnosed with 
COPD between 2003 and 2015, and 58.8% of cases were 
males. Most patients were diagnosed with COPD be-
tween 70 and 79 years of age. COPD patients tended to 
have high socioeconomic status, urban residence, and a 
high Charlson comorbidity index. There was a total of 
3,695 deaths (26.2%) in COPD patients during the study 
period.
Mortality rate
The number of individuals who were newly diagnosed 
with COPD varied slightly during 2003 to 2015, but the 
annual number did not show a significant trend toward 
increase or decrease. Table 2 shows the annual cumula-
tive numbers of newly diagnosed COPD patients. The 
number of incidents was the lowest in 2006 at 1,164 and 
the highest in 2012 at 1,538. The absolute number of an-
Table 1. Baseline demographics of patients with chronic obstructive pulmonary disease 
Variable Total (n = 14,127) Male (n = 8,301) Female (n = 5,826)
Age, yr
40–49 946 (6.7) 495 (6.0) 451 (7.7)
50–59 2,058 (14.6) 1,192 (14.4) 866 (14.9)
60–69 3,881 (27.5) 2,449 (29.5) 1,432 (24.6)
70–79 4,670 (33.1) 2,832 (34.1) 1,838 (31.6)
≥ 80 2,572 (18.2) 1,333 (16.1) 1,239 (21.3)
Household income
1st quintile 2,356 (16.7) 1,281 (15.4) 1,075 (18.5)
2nd quintile 1,955 (13.8) 1,148 (13.8) 807 (13.9)
3rd quintile 2,300 (16.3) 1,384 (16.7) 916 (15.7)
4th quintile 2,927 (20.7) 1,784 (21.5) 1,143 (19.6)
5th quintile 4,589 (32.5) 2,704 (32.6) 1,885 (32.4)
Region of residence
Urban 11,393 (80.6) 6,733 (81.1) 4,660 (80.0)
Rural 2,734 (19.4) 1,568 (18.9) 1,166 (20.0)
Charlson comorbidity index
0 2,067 (14.6) 1,305 (15.7) 762 (13.1)
1 3,826 (27.1) 2,212 (26.7) 1,614 (27.7)
2 3,493 (24.7) 2,055 (24.8) 1,438 (24.7)
≥ 3 4,741 (33.6) 2,729 (32.9) 2,012 (34.5)
Mortality 3,695 (26.2) 2,525 (30.4) 1,170 (20.1)
Values are presented as number (%).
Table 2. Annual newly diagnosed chronic obstructive pul-
monary disease patients
Year No. (%) Cumulative no. (%)
2003 1,346 (9.5) 1,346 (9.5)
2004 1,280 (9.1) 2,626 (18.6)
2005 1,188 (8.4) 3,814 (27.0)
2006 1,164 (8.2) 4,978 (35.2)
2007 1,217 (8.6) 6,195 (43.9)
2008 1,269 (9.0) 7,464 (52.8)
2009 1,336 (9.5) 8,800 (62.3)
2010 1,263 (8.9) 10,063 (71.2)
2011 1,321 (9.4) 11,384 (80.6)
2012 1,538 (10.9) 12,922 (91.5)
2013 1,205 (8.5) 14,127 (100.0)
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nual deaths in COPD patients also increased. The mean 
follow-up duration of the whole population was 51.9 ± 
37.8 months. The mortality rates of all COPD patients 1 
and 5 years after diagnosis were 9.5% and 25.4%, respec-
tively. The mortality rates differed significantly by sex 
and age (Figs. 2 and 3). The 5-year mortality rate in males 
was 1.5 times higher than in females (29.9% vs. 19.1%). 
The mortality rate increased rapidly with age. The 5-year 
mortality rate grouped by age 40 to 49, 50 to 59, 60 to 69, 
70 to 79, and 80 to 89 was 3.1%, 7.8%, 14.1%, 30.4%, and 
55.1%, respectively.
Causes of death
The most common causes of death in COPD were 
chronic lower respiratory disease (17.5%), lung cancer 
(15.1%), cardiovascular disease (8.3%), and cerebrovascu-
lar disease (6.5%) (Fig. 4). Lung cancer was the most com-
mon cause of death in men. Cardiovascular disease and 
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Figure 4. Causes of death in chronic obstructive pulmonary disease patients. CLRD, chronic lower respiratory disease; Cardio-
VD, cardiovascular disease; CerebroVD, cerebrovascular disease; DM, diabetes mellitus; HTN, hypertension.
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Figure 2. Survival curves of chronic obstructive pulmonary 
disease (COPD) patients by gender. 
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Figure 3. Survival curves of chronic obstructive pulmonary 
disease (COPD) patients by age. 
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cerebrovascular disease were common in women. 
DISCUSSION
This is the first study to describe long-term mortality in 
COPD patients using a large population-based cohort in 
Korea. The 5-year mortality rate of COPD was 25.4%. The 
mortality rate was higher in males (29.9 % vs. 19.1%). The 
common causes of death in COPD were chronic lower 
respiratory disease, lung cancer, cardiovascular disease, 
and cerebrovascular disease.
Although the prevalence of COPD is well known in 
Korea, associated mortality has not previously been de-
scribed. Globally, the prevalence of COPD is estimated 
as 11.7% [8]. The prevalence in Korea was 13.4% in those 
over 40 years of age in 2008, 19.4% in males, and 7.9% 
in females [9]. Although the mortality rate of COPD has 
not previously been reported in Korea, annual statistics 
on causes of death in Korea have included the mortality 
rate of chronic lower airway disease [10]. Based on that 
report, the mortality rate of chronic lower airway dis-
ease has not change significantly over the past decade 
(from 14.4/100,000 in 2006 to 14.1/100,000 in 2014), and 
only 2.7% of all deaths in Korea are due to chronic low-
er airway disease. Chronic lower airway disease includes 
bronchitis, emphysema, COPD, asthma, and bronchiec-
tasis according to the Korean Standard Classification of 
Disease and Cause of Death; accordingly, the reported 
mortality from pure COPD in Korea is very low.
Several studies have recently reported on the long-term 
mortality rate in COPD patients. Studies of hospitalized 
patients with acute exacerbation of COPD (AECOPD) re-
port relatively high long-term mortality. One study has 
recounted a 1-year mortality of 26.2%, while 5-year mor-
tality was 64.3% in patients admitted for AECOPD [11]. 
A similar study, which also analyzed patients with AE-
COPD, observed a long-term mortality (about 9 years) of 
COPD of 79% [12]. Population-based or outpatient-based 
studies have reported lower long-term COPD mortali-
ty than inpatient-based studies. One study in patients 
aged 65 and older patients found a COPD mortality rate 
of 56.9% after 12 years of follow-up [13]. Another study 
determined that the cumulative mortality of COPD over 
7 years was 34.0%, compared to 12.0% in the non-COPD 
population [14]. In subjects aged 65 to 100 years, COPD 
mortality at 5, 10, and 15 years was 32%, 62%, and 75%, re-
spectively [15]. We found a relatively low long-term mor-
tality rate of COPD (25.4% 5-year mortality) because we 
included a younger population than other studies.
Although there are no studies of mortality trends from 
COPD in Korea, other countries have reported their sta-
tistics. In the United States, the age-adjusted COPD mor-
tality rate has declined since 1999 [16]. The mortality rate 
was 63.7 per 100,000 people in 2011. However, the mor-
tality rate in women has increased since 1999. In Europe, 
age-adjusted rates of COPD mortality decreased from 
1994 to 2010 with a larger decrease in men and relatively 
stable rates in women [17]. The mortality rate per 100,000 
people in 2010 was 61.33 in men and 25.15 in women. In 
China, the age-standardized COPD mortality rate de-
creased from 1990 to 2013 in both males and females [18]. 
The mortality rate in 2013 was 79.4 per 100,000 people. 
In Japan, age-adjusted COPD mortality decreased from 
1950 to 2004 in both men and women [19]. The mortality 
rate per 100,000 people in 2004 was 19.7 in men and 4.3 
in women. In all countries, the overall age-adjusted mor-
tality from COPD has declined in recent years.
We found that chronic lower respiratory disease, lung 
cancer, and cardiovascular disease were the common 
causes of COPD mortality. This result was consistent 
with other studies [20-22]. The most frequent cause of 
death in COPD patients was deterioration of COPD. The 
Towards a Revolution in COPD Health (TORCH) study 
reported that 35% of COPD deaths were caused by pulmo-
nary diseases [21]. However, only 17.5% of COPD patients 
in our study died from chronic lower respiratory dis-
ease. COPD might be underreported as a cause of death 
because COPD patients often die with other diseases. 
Previous studies have reported that one-third of COPD 
patients die from cardiovascular disease [21,23]. In fact, 
the mortality rate of chronic lower respiratory disease in 
Korea has been unchanged since 2006, while the mortal-
ity rate of COPD comorbidities such as pneumonia, lung 
cancer, and cardiovascular disease has increased [10].
The quality of death certificates could be the main 
problem with the COPD mortality analysis. Some stud-
ies suggest that COPD is underreported as a cause of 
death, which could lead to underestimation of the mor-
tality burden from COPD. A study examining causes of 
death using data from the Copenhagen City Heart Study 
found that, among subjects with very severe COPD, only 
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24.9% had COPD listed as a cause of death [24]. The study 
also found that more than half of patients with very se-
vere COPD did not have COPD mentioned on their 
death certificate. A similar outcome has been reported 
from a study in China, which found that a national vital 
registration system had 73.5% sensitivity for COPD as a 
cause of death [25]. Collectively, these findings suggest 
that estimates of COPD as a cause of death need to be 
reviewed carefully, and that death in COPD patients is 
closely associated with vascular disease mortality.
This study had limitations. First, we could not use 
spirometry data. We used only ICD-10 codes and med-
ications for COPD diagnosis, which could result in se-
lection bias. However, Korean NHIS only reimbursed 
the cost of inhaled long-acting bronchodilators when 
patients received spirometry and satisfied the criteria of 
airflow limitation. Therefore, by implication, physicians 
prescribed inhaled long-acting bronchodilators on the 
basis of spirometry. Second, individuals only took oral 
medications could be included as COPD patients. The 
main treatment of COPD is obviously inhalers. How-
ever, previous studies in Korea have showed that oral 
medications were prescribed frequently for COPD man-
agement, even more than inhalers [4,6,26]. Our working 
definition including oral agents as COPD medications 
has been utilized and validated in many previous studies 
[4-6]. Third, COPD patients without healthcare could not 
be included. Our results might not apply to all COPD pa-
tients in the general population, especially mild COPD 
patients without healthcare use. The male proportion of 
58.5% in our study was lower than that of previous stud-
ies [9,27]. There is a possibility that healthcare use of men 
might be less than that of women [28,29], and under-di-
agnosis of COPD might be more frequent in men. Sim-
ilar to our study, previous COPD studies using Korean 
Health Insurance Review and Assessment Service data-
base also reported relatively low male proportions [4-6].
In conclusion, this is the first population-based study 
that described long-term mortality in COPD patients in 
Korea. The 5-year mortality of COPD patients was about 
25.4%. Higher mortality was observed in males and the 
elderly. The 5-year mortality rate in males was about 1.5 
times higher than in females. The common causes of 
death in COPD were chronic lower respiratory disease 
and lung cancer.
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